AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Multiple Sclerosis

Recent research efforts aimed at curing Multiple Sclerosis.

Last updated

Multiple Sclerosis

Overview

Multiple sclerosis (MS) is a lifelong immune-mediated disease in which inflammation damages myelin—the insulating layer around nerve fibers—and can also injure the nerve fibers themselves in the brain and spinal cord. Symptoms vary widely and can include visual problems, altered sensation, weakness, fatigue, imbalance, pain, and cognitive changes. MS follows different patterns: some people experience relapses followed by partial recovery, while others accumulate disability more gradually. Prognosis is highly individual; many people remain active for years, and life expectancy can be normal or close to normal, but MS is currently incurable. MedlinePlus overview

Current care combines disease-modifying therapies (DMTs), which reduce inflammatory relapses and new MRI lesions, with treatment of relapses, rehabilitation, symptom management, and preventive health care. High-efficacy DMTs can be used early for people at greater risk of aggressive disease, but they do not reliably stop progression in established progressive MS or rebuild lost myelin and nerve connections. 2023 treatment consensus MedlinePlus overview

Scope of Recent Research (2020–present)

MS cure research has been especially active since 2020, converging on three connected goals: permanently reset the harmful immune response, repair myelin and protect nerves, and prevent disease before symptoms begin. The field is closer to durable treatment-free remission for selected people with highly inflammatory MS than to a universal cure, because successful treatment must control both peripheral immune attacks and inflammation already compartmentalized inside the central nervous system while restoring damaged tissue. Pathways to Cures roadmap Refined Pathways to Cures roadmap

Major Breakthroughs and Emerging Therapies

The most clinically mature “immune reset” approach is autologous hematopoietic stem-cell transplantation (AHSCT). Doctors collect a person’s blood-forming stem cells, use intensive chemotherapy to remove much of the existing immune repertoire, and return the stored stem cells so a new immune system can develop. Recent expert guidance concludes that AHSCT can control inflammatory activity for long periods, particularly in younger, ambulatory people with highly active relapsing-remitting MS, but it is not established as a cure and appears less effective for non-inflammatory progressive disease. AHSCT position paper

A rapidly advancing strategy is CD19-directed CAR-T cell therapy, in which a patient’s T cells are engineered to eliminate CD19-positive B cells, including populations that may persist in the central nervous system despite standard antibody-based B-cell depletion. In a 2024 report of two people with progressive MS treated with KYV-101, CAR-T cells were detected in cerebrospinal fluid, neither patient developed immune-effector neurotoxicity, and one showed a sustained reduction in antibody production within the central nervous system; these are encouraging mechanistic observations, not proof of clinical efficacy. First KYV-101 MS report A related preclinical approach engineers regulatory T cells—immune cells that suppress excessive immune reactions—to recognize myelin oligodendrocyte glycoprotein (MOG), aiming to restore antigen-specific tolerance rather than broadly suppress immunity; it remains laboratory-stage research. MOG-specific CAR-Tregs

Interim results disclosed on October 23, 2026, from Bristol Myers Squibb’s phase 1 Breakfree-2 trial of zolacabtagene autoleucel (zola-cel), another autologous CD19 CAR-T product, reported stability or improvement in disability in 22 of 24 evaluable progressive-MS participants and no new MRI activity in all 24. However, this was a small, single-arm company-reported analysis with limited follow-up, a primary endpoint of safety, and serious treatment risks: cytokine-release syndrome occurred in 42.4%, neurotoxicity occurred in 7.6%, and one participant died after severe complications. The results should therefore be treated as preliminary rather than evidence of cure. Breakfree-2 interim results

Repair-focused research seeks to make new myelin, which could preserve damaged axons and potentially improve function. A phase 2a trial of the retinoid drug bexarotene did not improve its primary MRI remyelination measure and caused frequent thyroid, lipid, skin, and blood-cell adverse effects, illustrating the difficulty of translating animal repair results into tolerable human therapies. CCMR One bexarotene trial In contrast, a small 2022 study found that rHIgM22—an antibody designed to bind myelin and oligodendrocytes—reached cerebrospinal fluid after relapse and was generally tolerated, but it was a safety study in only 27 participants and did not demonstrate functional repair. rHIgM22 phase 1 trial Across remyelination trials, promising signals remain difficult to interpret because studies are small, short, and use varied imaging and visual-system outcomes. Remyelination-trial systematic review

A final disease-modifying direction targets Epstein–Barr virus (EBV), a leading causal candidate in MS. A large longitudinal study of more than 10 million U.S. military personnel found a 32-fold increase in MS risk after EBV infection, strengthening the rationale for EBV prevention and targeted immune therapies. EBV longitudinal study Yet the first major EBV-targeted cellular-therapy test has also supplied an important negative result: Atara’s phase 1/2 ATA188 trial in progressive MS was terminated after its primary endpoint was not achieved. ATA188 EMBOLD trial record

Clinical Trials and Experimental Approaches

The pivotal AHSCT question is being tested in BEAT-MS, a randomized phase 3 trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The trial is recruiting people with treatment-resistant relapsing MS and compares AHSCT against best available DMT; no results were posted as of October 24, 2026. BEAT-MS trial record BEAT-MS at Mayo Clinic

CAR-T development has moved from isolated compassionate-use cases to formal studies. Stanford is recruiting a phase 1, open-label KYV-101 study for non-relapsing progressive MS, while Kyverna’s planned KYSA-7 phase 2 program is designed for refractory primary and secondary progressive MS. Stanford MS trials Novel MS treatments review Breakfree-2 is also a phase 1, multicenter dose-escalation study of zola-cel for relapsing and progressive MS; its early readout is notable but requires controlled trials, longer follow-up, and independent peer-reviewed reporting. Breakfree-2 interim results

Methodologies and Scientific Approaches

Researchers combine immune profiling of blood and cerebrospinal fluid with MRI measures of inflammation, brain and spinal-cord volume, and chronic active lesions. Repair trials increasingly use quantitative markers such as magnetization-transfer ratio, myelin-water fraction, optical coherence tomography, and visual evoked potentials to look for myelin repair before waiting years for changes in disability. Remyelination-trial systematic review CAR-T studies additionally track engineered-cell expansion, B-cell depletion, cerebrospinal-fluid penetration, immunoglobulin production, and cytokine-release or neurologic toxicities. First KYV-101 MS report Breakfree-2 interim results

Preclinical work uses immune-mediated animal models of MS, human immune-cell cultures, patient-derived samples, and increasingly engineered cell platforms. The central translational challenge is to find therapies that stop damaging immune activity without impairing protective immunity, then pair them with approaches that remyelinate lesions, protect axons, or restore neural function. MOG-specific CAR-Tregs Pathways to Cures roadmap

Leading Institutions and Funding

Major academic and clinical centers include Stanford University, the University of California San Francisco, University Medical Center Hamburg-Eppendorf, Mayo Clinic, Cleveland Clinic, Cambridge, University College London, and major AHSCT programs across Europe and North America. Industry participants include Kyverna Therapeutics and Bristol Myers Squibb in CAR-T development, while Acorda Therapeutics and academic collaborators have supported rHIgM22 research. Stanford MS trials AHSCT position paper rHIgM22 phase 1 trial

The National MS Society’s Pathways to Cures program organizes research around stopping MS, restoring function, and preventing new cases. It reported more than $19 million in new commitments and annual investment exceeding $30 million for more than 200 new and ongoing studies in a recent funding cycle. National MS Society research commitment U.S. National Institutes of Health categorical spending for MS was reported at $112 million in fiscal year 2025, although this category is an estimate of relevant NIH-supported activity rather than a dedicated cure-development budget. NIH categorical spending

Strengths, Limitations, and Challenges

The field’s greatest strength is that it now addresses MS as both an immune and a repair problem. AHSCT provides proof that deep immune resetting can produce prolonged control of inflammatory MS, while CAR-T therapy may reach B-cell populations in the central nervous system that conventional therapies incompletely affect. AHSCT position paper First KYV-101 MS report The equally important limitation is that suppression of inflammation does not automatically restore neurons or reverse long-standing disability, especially in progressive MS. Remyelination-trial systematic review

Safety, scalability, and access are substantial barriers. AHSCT requires chemotherapy and specialist transplant care; CAR-T requires individualized cell manufacturing, lymphodepleting treatment, prolonged monitoring, and management of infection, cytokine-release syndrome, neurotoxicity, and potentially lasting antibody deficiency. AHSCT position paper Breakfree-2 interim results Progress is also slowed by heterogeneous disease courses, limited validated repair endpoints, small early trials, and barriers to pooling international data and biospecimens. Refined Pathways to Cures roadmap

Outlook and Future Directions

As of October 24, 2026, MS has no proven cure. The most realistic near-term milestone is durable, treatment-free remission for carefully selected people with active inflammatory disease through immune-reset approaches, followed by rigorous confirmation that benefit persists without unacceptable toxicity. The decisive next steps are randomized AHSCT evidence from BEAT-MS; controlled, longer-term CAR-T trials that demonstrate sustained disability benefit and manageable safety; and repair trials that link objective remyelination biomarkers to meaningful recovery in daily life. A broadly applicable cure will likely require prevention or early immune intervention plus successful neural repair, rather than a single treatment alone. BEAT-MS trial record Refined Pathways to Cures roadmap

References

Don't see your disease? Request a report